Bevacizumab in Combination with Taxane versus Non-Taxane Containing Regimens for Advanced/Metastatic Nonsquamous Non–Small-Cell Lung Cancer: A Systematic Review. Issue 8 (August 2015)

• Record Type: Journal Article
• Authors: Behera, Madhusmita; Pillai, Rathi N.; Owonikoko, Taofeek K.; Kim, Sungjin; Steuer, Conor; Chen, Zhengjia; Saba, Nabil F.; Belani, Chandra P.; Khuri, Fadlo R.; Ramalingam, Suresh S.
• Is Part Of: Journal of thoracic oncology. Volume 10:Issue 8(2015)
• Publication Date: 2015-08
• Subjects: bevacizumab -- taxanes -- systematic review; Chest -- Cancer -- Periodicals; Thoracic Neoplasms -- Periodicals; 616.99494005
• DOI: 10.1097/JTO.0000000000000572
• Languages: English
• ISSNs: 1556-0864

Abstract

Abstract : Background: In preclinical studies, the efficacy of the combination of antiangiogenic agents with chemotherapy seems to be dependent on the specific cytotoxic agent. We conducted a systematic review of the efficacy of bevacizumab in combination with taxane or non-taxane containing regimens for untreated, nonsquamous non–small-cell lung cancer patients. Methods: An extensive search of published clinical trials was conducted from electronic databases (MEDLINE, EMBASE, and Cochrane) and meeting proceedings using relevant search criteria. Phase 2 and randomized trials reporting on the efficacy of bevacizumab combined with taxane or non-taxane regimens were selected. A systematic analysis of extracted data was performed using Comprehensive Meta-Analysis (Version 2.2) software. Clinical outcome in patients treated with taxane versus non-taxane regimen was compared using point estimates for weighted values of median overall survival, progression-free survival, and response rate. Results: Twenty-nine studies reported between 2005 and 2015 were eligible. A total of 5890 patients (2767 and 3123 in the taxane and non-taxane groups, respectively) were included. The taxane and non-taxane groups were comparable in patient characteristics: median age, 62.8 versus 61.2 years; males, 57% versus 58%; adenocarcinomas, 83% versus 83%; stage IV, 87% versus 82%; performance status 0/1- 45/55% versus 41/59%, respectively. The weighted median overall survival was 14.4 versus 13.7 months ( p = 0.5); progression-free survival was 6.93 versus 6.99 months ( p = 0.61); response rate was 41% versus 39% ( p = 0.65) for taxane and non-taxane groups. Conclusions: The outcomes between taxane and non-taxane regimens when given in combination with bevacizumab for patients with nonsquamous non–small-cell lung cancer are comparable.